- HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics have entered a strategic agreement to support development and GMP manufacturing of Antibody Protease Inhibitor Conjugates (APICs).
- The collaboration combines bioconjugation and manufacturing expertise with Biodelphis’ APIC therapeutic platform to support clinical development.
HAS Healthcare Advanced Synthesis and Biodelphis Therapeutics have signed a strategic agreement focused on the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates (APICs), a class of targeted therapeutics designed to inhibit disease-driving proteases.
Under the collaboration, the companies will combine HAS Group’s expertise in bioconjugation, process development, and clinical-grade manufacturing with Biodelphis Therapeutics’ APIC platform. The partnership is intended to support the advancement of first-in-class APIC candidates from early-stage development into scalable manufacturing processes suitable for clinical evaluation.
The companies stated that the agreement aims to integrate therapeutic design and contract manufacturing capabilities to strengthen the path toward clinical development. HAS and Cerbios will provide support for high-quality bioconjugate production as part of the collaboration.
